Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study.
暂无分享,去创建一个
J A Blessing | P. Rose | P G Rose | H D Homesley | H. Homesley | J. Blessing | A R Mayer | A. Mayer
[1] J. Garcia-conde,et al. Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] N. Nissen,et al. Schedule dependency of the antileukemic activity of the podophyllotoxin-derivative VP 16-213 (NSC-141540) in L1210 leukemia. , 2009, Acta pathologica et microbiologica Scandinavica. Section A, Pathology.
[3] M. Slevin,et al. Predicting etoposide toxicity: relationship to organ function and protein binding. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Hainsworth,et al. Chronic daily administration of oral etoposide--a phase I trial. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] H. Hansen,et al. Phase II clinical trial of VP-16-213 in ovarian cancer. , 1981, Cancer treatment reports.
[6] J. Karp,et al. The secondary leukemias: challenges and research directions. , 1996, Journal of the National Cancer Institute.
[7] R. Barakat,et al. Follow-up of Memorial Sloan-Kettering Cancer Center patients treated on National Cancer Institute Treatment Referral Center protocol 9103: paclitaxel in refractory ovarian cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] M. Gore,et al. Protracted oral etoposide in epithelial ovarian cancer: a phase II study in patients with relapsed or platinum-resistant disease. , 1994, British Journal of Cancer.
[9] D G Lowe,et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Thigpen,et al. Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] H. Senn,et al. VP-16-213 monotherapy for remission induction of small cell lung cancer: a randomized trial using three dosage schedules. , 1978, Cancer treatment reports.
[12] M. Gore,et al. Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] J. Edmonson,et al. Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agents. , 1978, Gynecologic oncology.
[14] J. Hainsworth,et al. Bioavailability of low-dose oral etoposide. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory to or relapsing within 12 months after platinum-containing chemotherapy. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] F. Behm,et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. , 1991, The New England journal of medicine.
[17] N. Nissen,et al. Clinical investigation of a new podophyllum derivative, epipodophyllotoxin, 4'-demethyl-9-(4,6-O-2-thenylidene- -D-glucopyranoside) (NSC-122819), in patients with malignant lymphomas and solid tumors. , 1972, Cancer chemotherapy reports.
[18] P. Rose,et al. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. , 1996, Gynecologic oncology.
[19] B. Bundy,et al. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study. , 1979, Cancer treatment reports.
[20] F. Hansen,et al. Phase II clinical trial of VP-16-213 (etoposide) administered orally in advanced ovarian cancer. , 1990, Gynecologic oncology.
[21] L. Liu,et al. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA cleavage. , 1984, Cancer research.
[22] R. Reznek,et al. A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] K. Swenerton,et al. Oral etoposide is active against platinum-resistant epithelial ovarian cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] Edmund E. Kim,et al. Phase II study of intravenous topotecan as a 5-day infusion for refractory epithelial ovarian carcinoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] PROLONGED ADMINISTRATION OF ORAL ETOPOSIDE IN PREVIOUSLY TREATED EPITHELIAL OVARIAN CANCER. A PHASE II TRIAL , 1992 .
[26] J. Whitlock,et al. Epipodophyllotoxin‐related leukemia. Identification of a new subset of secondary leukemia , 1991, Cancer.
[27] M. Markman,et al. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. , 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.